An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study

Phase 4

Recruiting

• Conditions: Parkinson; Parkinson's disease; 10028037

• Registration Number: NL-OMON36779
• Lead Sponsor: TEVA Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 7

Inclusion Criteria

1. Patients who participated in the Adagio study
2. Patients who are currently using rasagiline, are willing to restart treatment, and in the opinion of the investigator will gain clinical benefit from restarting treatment)
3. Patients with Parkinson's disease

Exclusion Criteria

1. Subjects who have discontinued rasagiline treatment due to an adverse event and have not restarted rasagiline treatment subsequently.
2. Subjects who cannot be given rasagiline due to any exclusion based on the local label (including pregnancy or nursing women) or due to the use of medications contraindicated for concomitant use with rasagiline according to local label
3. Subjects with a medical condition that is considered by the investigator as significant enough to prevent participation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>As this is a single arm study, all statistical analysis will be descriptive in<br /><br>nature.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>